Status:
COMPLETED
Fibers and Gut Health
Lead Sponsor:
Société des Produits Nestlé (SPN)
Conditions:
Constipation
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
Gastrointestinal discomfort regularly affects \>25% of the population worldwide. One of the major contributors to GI discomfort is constipation, which has a prevalence of \~15% and symptoms of which h...
Eligibility Criteria
Inclusion
- Men or women aged 18-75; female subjects of child-bearing potential must be willing to use a reliable method of contraception throughout the study period
- BMI: 18.5 - 29.9 kg/m2
- Recruitment based on simplified core ROME III diagnostic criteria for functional constipation (based on specific screening questions):a). average Bristol stool type of 1 - 4 AND frequency of 1 - 3 spontaneous bowel movements (SBMs) per week b). plus at least ONE of: straining on at least 25% of defaecations; sensation of incomplete evacuation on at least 25% of defaecations; sensation of anorectal obstruction / blockage on at least 25% of defaecations; use of manual manoeuvres on at least 25% of defaecations
- Cleveland Clinic constipation score (CCCS) of 8-20
- Low-moderate fiber intake (≤18g) determined by the semi-quantitative food intake screener known as the Block Fiber Screener
- Ability to understand the patient information sheet and instructions in Dutch, and able to provide informed consent
Exclusion
- Subjects who report lactose intolerance and/or are allergic to soy or cow milk protein
- Pregnant or breast-feeding women
- Ongoing other diagnosed gastrointestinal disease or complication (Crohn's disease, Coeliac disease, chronic diarrhoea)
- Any clinical relevant abnormalities in the screening visit medical examination or alarm features such as sudden unintentional weight loss, rectal bleeding, recent change in bowel habit (\<3 months), abdominal pain and stool positive for occult blood
- Prior abdominal surgery (including gastric bypass or laparoscopic banding), except cholecystectomy and appendicectomy
- Neurologic diseases such as multiple sclerosis, stroke, spinal cord injury, Hirschsprung disease
- Chronic medication that in opinion of the investigator would impact gut motility
- Illness that may preclude the subject's ability to complete the study or that may confound the study outcomes (e.g. bowel cancer, prostate cancer, terminal illness, severe cardiovascular disease, chronic renal failure or eating disorders) or any other serious illness resulting in \>2 weeks inability to work in the 3 months before the study start
- Subjects with co-morbid illnesses such as cardiovascular, endocrine, renal or other chronic disease likely to affect gut motility or limit normal functions (e.g. reduced mobility or increased fragility)
- Ongoing alcohol, drug, or medication abuse (anamnesis only)
- Self-reported symptoms of pelvic organ prolapse
- Moderate or severe active local anorectal problems such as recurrent anal fissures, bleeding, large prolapsing haemorrhoids
- Regular use of fiber supplementation (e.g. Fybogel, Lactulose) (i.e. no more than 1 standard dose) over the week prior to the screening visit and no more than 6 standard doses in the past 1 month prior to the screening visit
- Participation in another study with any investigational product within 3 months of screening
- Investigator believes that the participant is physically or mentally unfit to participate in the trial
Key Trial Info
Start Date :
October 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2015
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT02234518
Start Date
October 1 2014
End Date
October 1 2015
Last Update
November 10 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Julius Clinical
Zeist, Netherlands, 3703 CD